Clinical Trial Detail

NCT ID NCT02286843
Title Can HER2 Targeted 89Zr-trastuzumab PET/CT Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements yes
Sponsors Memorial Sloan-Kettering Cancer Center
Indications

Her2-receptor negative breast cancer

Therapies

Trastuzumab

Age Groups: adult

Additional content available in CKB BOOST